Gujarat Themis Biosyn Ltd vs Kwality Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 382.7 as of 05 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Kwality Pharmaceuticals Ltd changed from 3.8 on March 2021 to 22.6 on March 2025 . This represents a CAGR of 42.84% over 5 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Kwality Pharmaceuticals Ltd changed from ₹ 58.11 crore on March 2021 to ₹ 901.74 crore on March 2025 . This represents a CAGR of 73.05% over 5 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Kwality Pharmaceuticals Ltd for the Dec '25 is ₹ 123.97 crore as compare to the Sep '25 revenue of ₹ 111.95 crore. This represent the growth of 10.74% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Kwality Pharmaceuticals Ltd for the Dec '25 is ₹ 29.65 crore as compare to the Sep '25 ebitda of ₹ 26.25 crore. This represent the growth of 12.95% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Kwality Pharmaceuticals Ltd changed from ₹ 8.35 crore to ₹ 16 crore over 7 quarters. This represents a CAGR of 45.01% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Kwality Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Limited was Incorporated on May 4th 1983 when its founder Mr. Ramesh Arora was inspired to begin his own venture leaving behind the already flourishing family business of spinning and aromatics.
With little background of finished pharmaceuticals and high held spirits and will, he started this business.
He received his first drug license in 1981 approved for liquid oral manufacturing.
Presently, the Company has 56 different sections available at their production centres. Kwality Pharmaceuticals Ltd. are manufacturer of finished pharmaceutical formulations in a Liquid Orals, Dry Syrups, Tablets, Capsules, Sterile Powder for Injections and small volume injectables.
The Company has the most modern & sophisticated Plant, Equipment, technique, and workforce.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Kwality Pharmaceuticals Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Kwality Pharmaceuticals Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,170 Cr while Market cap of Kwality Pharmaceuticals Ltd is 1,720 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Kwality Pharmaceuticals Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Kwality Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Kwality Pharmaceuticals Ltd?

As of May 5, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹382.7. On the other hand, Kwality Pharmaceuticals Ltd stock price is INR ₹1658.15.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Kwality Pharmaceuticals Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Kwality Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.